Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22821448 | 0.92 | HSD17B10 (0.47) | HSD17B10ALDH1A1HTTSLC6A9S1PR1 | |
| SCHEMBL20202579 | 0.92 | HSD17B10 (0.47) | HSD17B10ALDH1A1HTTGAASIGMAR1 | |
| SCHEMBL15985745 | 0.92 | HSD17B10 (0.47) | HSD17B10ALDH1A1HTTGAASIGMAR1 | |
| SCHEMBL22815172 | 0.92 | HSD17B10 (0.47) | HSD17B10ALDH1A1HTTGAASIGMAR1 | |
| SCHEMBL22661894 | 0.90 | HSD17B10 (0.48) | HSD17B10ALDH1A1HTTGAASIGMAR1 | |
| SCHEMBL12018111 | 0.90 | HSD17B10 (0.48) | HSD17B10ALDH1A1HTTGAASIGMAR1 | |
| SCHEMBL10317239 | 0.90 | HSD17B10 (0.48) | HSD17B10ALDH1A1HTTGAASIGMAR1 | |
| SCHEMBL9119001 | 0.90 | HSD17B10 (0.48) | HSD17B10ALDH1A1HTTGAASIGMAR1 | |
| SCHEMBL1142728 | 0.90 | HSD17B10 (0.48) | HSD17B10ALDH1A1HTTGAASIGMAR1 | |
| SCHEMBL27255807 | 0.90 | HSD17B10 (0.48) | HSD17B10ALDH1A1HTTGAASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE | 2024-06-27 | — | — | US | disclosed |
| WO-2024056805-A1 | NEW PET TRACER FOR IMAGING OF THE FUNCTIONAL HEPATIC RESERVE | MEDIZINISCHE UNIVERSITÄT INNSBRUCK (AT) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023215333-A1 | RADIOPHARMACEUTICAL AND METHODS | Point Biopharma, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-10-19 | — | — | US | disclosed |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2020256546-A1 | COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2020-12-24 | — | — | WO | disclosed |
| US-20170050989-A1 | Molecular Imaging Probes | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-02-23 | — | — | US | disclosed |
| US-20170050989-A1 | Molecular Imaging Probes | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-02-23 | — | — | US | disclosed |
| WO-2015085005-A1 | MOLECULAR IMAGING PROBES | THE GENERAL HOSPITAL CORPORATION (US) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050989-A1 | Molecular Imaging Probes | SLC10A1, CFTR, FIBP | HSD17B10 803/4885ALDH1A1 66/4885HTT 4143/4885 |
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | FAP, APC, FIBP | HSD17B10 3607/4885ALDH1A1 1322/4885HTT 2824/4885 |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | FAP, APC, FIBP | HSD17B10 3607/4885ALDH1A1 1322/4885HTT 2824/4885 |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | BCL6B, BCL6, BTD | HSD17B10 2957/4885ALDH1A1 3873/4885HTT 627/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | HSD17B10 3848/4885ALDH1A1 3906/4885HTT 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.